21世纪经济报道记者 申俊涵 北京报道 7月29日，"并购破局：存量时代的投退博弈"闭门研讨会在北京成功举办。现场，来自政府投资基金、 产业资本、GP/LP及中介机构的50余位嘉宾齐聚一堂，围绕并购市场的政策趋势、机遇与挑战，并购投 资的交易实践等话题，展开精彩分享和深度讨论。 会上，爱尔眼科董事、副总经理兼董事会秘书吴士君分享了爱尔眼科的并购实践经验。据了解，爱尔眼 科从2009年前后开始做并购，公司现有医疗机构中约半数是收购整合而来。同时，公司的并购标的分布 广泛，不仅涉及国内近30个省区，还包括在海外进行国际化并购。 如何对标的项目进行估值？据了解，市场中有市盈率、市净率、市销率、参考样本定价等各种各样的估 值方法。爱尔眼科会把现有的方法综合运用，再结合项目的具体情况，形成对项目的合理估值。值得注 意的是，在财务性收购中，主要关注项目本身的估值。但在战略性收购中，更要考虑到收购后对标的内 涵价值的增值成长。 吴士君回忆了爱尔眼科第一次做收购的情形：当时，那家医疗机构由两位著名的眼科医生创办，机构的 年收入为五六百万，并且连续多年增长不大。这笔收购从市盈率角度看估值并不低，最终，爱尔眼科还 是以双方满意的 ...

爱尔眼科属于医疗服务行业，是一家专注于眼科医疗服务的连锁医疗机构。公司通过"分级连锁"模式构 建覆盖全国的眼科医疗网络，并在全球范围内布局医疗、教学、科研及产业投资。 消息面上，爱尔眼科董事长陈邦近日获颁"优秀中国特色社会主义事业建设者"称号。陈邦带领爱尔眼科 从初创企业发展成为全球性眼科医疗集团，并通过创新模式推动医疗资源下沉，提升基层医疗服务能 力。公司还积极履行社会责任，累计支持公益项目873个，覆盖全国31个省份。 资金方面，7月30日主力资金净流出4293.02万元。 风险提示：股市有风险，投资需谨慎。 截至2025年7月30日收盘，爱尔眼科股价报13.16元，较前一交易日下跌0.53%，成交额达15.73亿元。 来源:金融界 ...

Core Viewpoint - The article highlights the journey of Aier Eye Hospital, founded by Chen Bang, emphasizing its mission to make eye care accessible to everyone, regardless of their financial status, and its significant impact on millions of lives through innovative healthcare solutions and community outreach efforts [2][5][8]. Group 1: Company Overview - Aier Eye Hospital was established in 2003 by Chen Bang in Changsha, with the vision of providing accessible eye care services globally, now operating 968 institutions [2][5]. - The company has developed a "graded chain" model, expanding its services from major cities to rural areas, covering over 90% of provincial capitals and 80% of prefecture-level cities in China [5][6]. Group 2: Innovation and Development - Aier Eye Hospital became the first medical institution in China to go public in 2009, with Chen Bang emphasizing that the IPO was a means to enhance service quality rather than an end goal [7]. - The company has introduced innovative solutions like the "Cloud Clip," an AI device for monitoring children's eye health, reflecting its commitment to addressing patient needs through technology [7]. Group 3: Social Responsibility - Over 21.35 billion yuan has been invested in public welfare initiatives, benefiting approximately 200 million people through eye disease treatment and education [8]. - The establishment of the Eye Care Public Welfare Foundation and initiatives like the "Precision Poverty Alleviation Light Journey" demonstrate the company's commitment to ensuring that eye health services are available to all, regardless of economic status [8].

Core Viewpoint - The chairman of Aier Eye Hospital, Chen Bang, stated that the company currently has no plans for a Hong Kong stock listing, citing strong fundraising capabilities and good cash flow as reasons for this decision [1]. Group 1 - The company has no immediate plans for a Hong Kong stock listing [1]. - The primary purpose of a Hong Kong listing would be to raise funds, but the company is currently in a strong financial position [1]. - Aier Eye Hospital's cash flow is described as very good, and the interest rates for bank loans are low [1]. Group 2 - The company will consider a Hong Kong listing only if there are particularly good investment opportunities and insufficient funding capabilities [1].

Industry Outlook - The ophthalmology medical service industry faces both opportunities and challenges, with a growing market size driven by an aging population and increasing demand for myopia prevention [2] - The market for cataract surgeries is expected to expand, while the refractive surgery market has significant growth potential due to low penetration rates [2] - National policies supporting private healthcare provide a favorable environment for the development of private ophthalmology hospitals [2] Current Market Performance - In 2024, the ophthalmology industry experienced a slowdown in growth due to intense domestic competition, low consumer demand, and policy impacts such as healthcare payment reforms [3] - Larger companies showed better profit resilience amidst these challenges, indicating a trend towards increasing market concentration [3] Company Performance - In Q1 2025, the company reported total revenue of CNY 742 million, a year-on-year increase of 9.82%, and a net profit of CNY 27 million, up 61.18% [4][7] - The company has effectively controlled costs and optimized its business structure through the introduction of new technologies [4] Future Growth Drivers - Future profit growth for the company is driven by six key factors: 1. Aging population and increased awareness of eye health driving demand for cataract and vision care services 2. Business structure optimization and promotion of high-end cataract projects to enhance profit margins 3. Introduction of advanced technologies to improve service attractiveness and gross margins 4. Gradual reduction of losses from newly opened hospitals, enhancing performance flexibility 5. Cost control through centralized procurement and digital management to improve operational efficiency 6. A strategic approach to investment expansion under a "national chain + local integration" model [5]

Group 1 - The core viewpoint of the news highlights the financial performance and market position of Puri Eye Hospital Group, indicating a recent stock price increase and a significant market capitalization of 6.586 billion yuan [1] - As of May 6, the stock closed at 44.02 yuan, reflecting a 2.28% increase, with a latest price-to-book ratio of 3.09, marking a new low in 16 days [1] - The company experienced a net outflow of 976,800 yuan in principal funds on May 6, with a total outflow of 23.9214 million yuan over the past five days, indicating a trend of capital withdrawal [1] Group 2 - In the first quarter of 2025, the company reported an operating income of 742 million yuan, representing a year-on-year increase of 9.82%, and a net profit of 27.2794 million yuan, which is a 61.18% increase compared to the previous year [2] - The company's sales gross margin stands at 39.34%, which is a critical indicator of its profitability [2] - The company has a price-to-earnings ratio (TTM) of -71.97, which is significantly lower than the industry average of 38.66, indicating potential undervaluation in the market [2]

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Insights - The company's performance in 2024 met expectations, with total revenue of 4.027 billion yuan, a year-on-year increase of 0.35%. However, the net profit attributable to the parent company decreased by 35.63% to 429 million yuan [6][12]. - The revenue breakdown for 2024 shows a decline in cataract project revenue by 11.56% to 873 million yuan, while the revenue from refractive projects increased by 7.44% to 1.296 billion yuan. The overall growth slowdown is attributed to changes in the industry environment, a temporary slowdown in demand, and intensified competition [2][12]. - The company is advancing its strategic acquisitions to expand its ophthalmology service network, having established 62 specialized hospitals and 66 optical centers across 48 cities in China by 2024 [12]. - The company emphasizes clinical discipline development and quality improvement in medical services, with two top-tier ophthalmology hospitals supporting clinical diagnosis, research innovation, and talent cultivation [12]. - The company has formed a three-tiered research innovation platform system and has received approval for five new research innovation platforms in 2024, along with 60 new medical research projects [12]. - Profit forecasts for the company indicate net profits of 540 million, 640 million, and 720 million yuan for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings ratios of 29, 25, and 22 times [12]. Financial Summary - In 2024, the total revenue is projected at 4.027 billion yuan, with a gross profit of 1.780 billion yuan, resulting in a gross margin of 44% [17]. - The company expects to see a gradual increase in revenue and net profit over the next three years, with total revenue projected to reach 5.235 billion yuan by 2027 [17].

Core Insights - The company reported a revenue of 20.983 billion yuan for 2024, representing a 3.0% increase, and a net profit attributable to shareholders of 3.56 billion yuan, up 5.9% [1] - The Q4 2024 single-quarter revenue was 4.68 billion yuan, an 8.4% increase, while the net profit attributable to shareholders decreased by 41.3% to 104 million yuan [2] - For Q1 2025, the company achieved a revenue of 6.026 billion yuan, a 16.0% increase, and a net profit of 1.05 billion yuan, up 16.7% [2] Financial Performance - The company's revenue from various segments in 2024 included: - Refractive and optical: 7.6 billion yuan (+2.3%) - Cataract: 3.49 billion yuan (+4.9%) - Anterior segment: 1.9 billion yuan (+6.0%) - Posterior segment: 1.5 billion yuan (+8.2%) - Gross margins for these segments were 55.1%, 34.7%, 41.2%, and 31.4% respectively, with slight declines year-over-year [2] - The expense ratios for 2024 were: - Sales: 10.3% - Management: 14.2% - R&D: 1.5% - Financial: 1.0% [2] Operational Highlights - The company recorded an outpatient volume of 16.94 million visits in 2024, a 12.1% increase, and performed 1.29 million surgeries, a 9.4% increase [3] - By the end of 2024, the company had established a global network of 974 medical facilities, with 811 in mainland China [3] - The overseas revenue reached 2.63 billion yuan, accounting for 12.5% of total revenue, indicating a growing international presence [3] Investment Outlook - The company adjusted its revenue forecasts for 2025 and 2026 to 23.43 billion yuan and 25.96 billion yuan, respectively, with growth rates of 11.7% and 10.8% [4] - The net profit forecasts for the same years are 4.07 billion yuan and 4.65 billion yuan, with corresponding growth rates of 14.5% and 14.2% [4] - The company maintains a "buy" rating with projected EPS of 0.44 yuan for 2025 and 0.50 yuan for 2026 [4]

Core Insights - The company reported a revenue of 20.983 billion yuan for 2024, a year-on-year increase of 3.02%, and a net profit attributable to shareholders of 3.556 billion yuan, up 5.87% [1] - In Q1 2025, the company achieved a revenue of 6.026 billion yuan, representing a year-on-year growth of 15.97%, and a net profit of 1.050 billion yuan, an increase of 16.71% [1] - The company demonstrated strong operational resilience despite a slowdown in the ophthalmology industry, with outpatient visits reaching 16.9407 million, a 12.14% increase, and surgical procedures totaling 1.2947 million, up 9.38% [1] Business Performance - The company’s refractive project revenue was 7.603 billion yuan, growing by 2.31%, while optical project revenue reached 5.279 billion yuan, increasing by 6.42% [1] - Cataract surgery revenue was 3.489 billion yuan, up 4.87%, and anterior segment surgery revenue was 1.898 billion yuan, growing by 5.95% [1] - Posterior segment surgery revenue amounted to 1.499 billion yuan, reflecting an 8.22% increase [1] Strategic Expansion - The company is enhancing its ophthalmology network, having established the Changsha Medical Center in 2024 to improve medical education and research capabilities [2] - Regional eye centers in Shanghai and Nanning have been completed, while facilities in Hubei, Anhui, Shenyang, and Guizhou are operational, and Beijing Aier Yingzhi is under construction [2] - The acquisition of 87 medical institutions has further strengthened the grassroots hospital network, and the company has entered the UK ophthalmology market through the acquisition of Optimax Group [2] Financial Forecast - Revenue projections for 2025-2027 are 23.681 billion, 27.084 billion, and 31.154 billion yuan, with corresponding growth rates of 12.86%, 14.37%, and 15.03% [3] - Net profit forecasts for the same period are 4.115 billion, 4.761 billion, and 5.615 billion yuan, with growth rates of 15.71%, 15.70%, and 17.95% [3] - The company is expected to maintain a strong position in the ophthalmology service sector, with a three-year CAGR of 16.45% [3]

Core Viewpoint - The company reported a steady growth in revenue and profit for 2024, with a notable increase in Q1 2025, indicating resilience in its operations despite external challenges [1][2]. Financial Performance - In 2024, the company's operating revenue reached 20.983 billion (yoy +3.02%), with a net profit attributable to shareholders of 3.556 billion (yoy +5.87%) and a non-recurring net profit of 3.099 billion (yoy -11.82%) [1]. - For Q1 2025, the company achieved an operating revenue of 6.026 billion (yoy +15.97%) and a net profit of 1.050 billion (yoy +16.71%), with a non-recurring net profit of 1.060 billion (yoy +25.78%) [1]. Business Segments - Revenue breakdown for 2024 includes: - Refractive surgery: 7.602 billion (yoy +2.31%) - Vision care: 5.278 billion (yoy +6.42%) - Cataract: 3.489 billion (yoy +4.87%) - Anterior segment projects: 1.897 billion (yoy +5.95%) - Posterior segment projects: 1.499 billion (yoy +8.22%) - Other projects: 1.142 billion (yoy -19.43%) [1]. Growth Drivers - The increase in average customer price for refractive surgery is expected to drive growth in this segment, while the high base effect from cataract surgeries is anticipated to normalize, leading to a potential recovery in growth rates [2]. - The company plans to introduce new surgical techniques, such as All-Laser LASIK and ICL V5, to meet diverse customer needs and further enhance average customer pricing in the refractive segment [2]. Cost Management - The company achieved a gross margin of 48.02% in Q1 2025 (yoy -0.28 percentage points), with reductions in sales, management, R&D, and financial expense ratios, leading to a total decrease in period expense ratio by 1.76 percentage points [2]. Future Projections - Revenue forecasts for 2025-2027 are 23.090 billion, 26.074 billion, and 29.224 billion, with corresponding growth rates of 10.0%, 12.9%, and 12.1% [3]. - Net profit projections for the same period are 4.031 billion, 4.700 billion, and 5.432 billion, with growth rates of 13.3%, 16.6%, and 15.6% [3].